Market Analysis and Insight: Europe Anticoagulation Therapy Market
Europe Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) – Industry Trends and Forecast to 2026
Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open. Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi. There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).
Europe anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.
Get a Sample Copy of report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-anticoagulation-therapy-market
Segmentation: Europe Anticoagulation Therapy Market
Europe anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.
- On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others
- On the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and others
- On the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others
- On the basis of route of administration, the market is segmented into oral and injectable
- On the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others
- On the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement
- On the basis of type, the market is segmented into generics and branded
- On the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others
- On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy
Competitive Analysis: Europe Anticoagulation Therapy Market
Some of the major players operating in the Europe anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.
Get Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=europe-anticoagulation-therapy-market
Recent Developments
- In September 2018, Sanofi announced Health got Canada approval for Lovenox’s (enoxaparin sodium) new indication toprevent thrombus formation in the extra-corporeal circulation during haemodialysis in patients who are having end stage kidney disease (ESKD). This will attract the potential consumers helping in the growth of the company.
- In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg. It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD). This approval will help the company to develop anticoagulant business in European countries.
- In June 2015, Daiichi Sankyo Company, Limited received the EU approval for LIXIANA (edoxaban). It is a branded version of edoxaban. It is developed to reduce chances of stroke and systemic embolism (SE) in patients having non-valvular atrial fibrillation (NVAF). This product approval will help to expand Daiichi’s product portfolio in Europe as company can market it in to all European States.
Research Methodology: Europe Anticoagulation Therapy Market
Primary Rependants:
Key Opinion Leaders (KOL’s): Manufacturers, Researchers, Distributors, Bakers and Food Industrialists.
Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and National Sales Managers.
For More Information or Query or Looking for Customization, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-anticoagulation-therapy-market
Browse more related report to know about market analysis
- Asia-Pacific Anti-Nuclear Antibody Test Market
- Asia-Pacific Rx Dermatology Topical Drug Delivery Market
- Europe Anticoagulation Therapy Market
- Europe Dry Eye Syndrome Treatment Market
- Ameloblastic Carcinoma Market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact: Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
Market Analysis and Insight: Europe Anticoagulation Therapy MarketEurope Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) – Industry Trends and Forecast to 2026Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open.
Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi.
There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).Europe anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.Get a Sample Copy of report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-anticoagulation-therapy-marketSegmentation: Europe Anticoagulation Therapy MarketEurope anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and othersOn the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and othersOn the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and othersOn the basis of route of administration, the market is segmented into oral and injectableOn the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and othersOn the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacementOn the basis of type, the market is segmented into generics and brandedOn the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and othersOn the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacyCompetitive Analysis: Europe Anticoagulation Therapy MarketSome of the major players operating in the Europe anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.Get Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=europe-anticoagulation-therapy-marketRecent DevelopmentsIn September 2018, Sanofi announced Health got Canada approval for Lovenox’s (enoxaparin sodium) new indication toprevent thrombus formation in the extra-corporeal circulation during haemodialysis in patients who are having end stage kidney disease (ESKD).
This will attract the potential consumers helping in the growth of the company.In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg.
It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD).
This approval will help the company to develop anticoagulant business in European countries.In June 2015, Daiichi Sankyo Company, Limited received the EU approval for LIXIANA (edoxaban).
The global anticoagulant reversal drugs market size is expected to reach USD 2.20 billion by 2028 according to a new study by Polaris Market Research.
The report “Anticoagulant Reversal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product (Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine); By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy); By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.Moreover, increased medical attention and awareness of the disease among individuals also supporting the region’s market growth.
Increased attention of the key players in the market in the booming region also complemented its market growth for anticoagulant reversal drugs.
Market participants such Portola Pharmaceuticals, CSL Behring, Bausch Health Companies Inc., Alps Pharmaceutical Ind.
Co., Ltd, Boehringer Ingelheim, Octapharma AG, AMAG Pharmaceuticals, Inc., Pfizer, Inc., Dr. Reddy’s Laboratories, SG Pharma Pvt Ltd., and Fresenius Kabi AG.Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/anticoagulant-reversal-drugs-market/request-for-sample The study objectives are:To analyze and research the global Anticoagulant Reversal Drugs Market capacity, production, value, consumption, status and forecast;To focus on the key Anticoagulant Reversal Drugs Market manufacturers and study the capacity, production, value, market share and development plans in next few years.To focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.To define, describe and forecast the market by type, application and region.To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.To identify significant trends and factors driving or inhibiting the market growth.To analyze the opportunities in the market for stakeholders by identifying the high growth segments.To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.Anticoagulant Reversal Drugs, by Regional Outlook (Revenue – USD Million, 2016 – 2028)North AmericaS.CanadaEuropeFranceGermanyUKItalySpainNetherlandsAustriaAsia PacificChinaIndiaJapanMalaysiaSouth KoreaIndonesiaCentral & South AmericaMexicoBrazilArgentinaMiddle East & AfricaUAESaudi ArabiaIsraelSouth AfricaGet Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/anticoagulant-reversal-drugs-market/request-for-discount-pricingAbout Polaris Market ResearchPolaris Market Research is a Middle East market research and consulting company.
The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.Contact Us:Polaris Market ResearchPhone: 1–646–568–9980Email: [email protected]: www.polarismarketresearch.com
Market Analysis and Insights:- Global Chronic Depressive Personality Disorder Treatment MarketGlobal Chronic Depressive Personality Disorder Treatment Market By Mechanism of Action (Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)), Drugs (Amitriptyline, Bupropion, Sertraline, Duloxetine), Diagnosis (Physical Exam, Lab Tests and Psychological Evaluation), Treatment (Medication and Psychotherapy), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2026 Market Analysis: Global Chronic Depressive Personality Disorder Treatment MarketGlobal chronic depressive personality disorder treatment market is growing at a steady CAGR in the forecast period of 2019-2026.
The report contains data of the base year 2018 and historic year 2017.
This rise in market value can be attributed to the increasing prevalence of depressive personality disorder, increase in diagnosis, requirement for long term treatment and increase in initiatives by government and non-government organizations regarding mental disorders by awareness campaigns and conference are some factors fueling the market growth.Market Definition: Global Chronic Depressive Personality Disorder Treatment MarketChronic depressive personality disorder is also known as dysthymia is a form of depression which is mild but continuously remains for several years.
A patient with chronic depressive personality disorder have symptoms such as lost interest in normal activities, hopelessness, low self-esteem, low appetite, low energy and an overall feeling of inadequacy.
These feelings interfere with the patient’s personal and social relationship, profession and daily activities.
This disorder can affect children and adolescents, approximately 11.2% of 13 to 18 years olds gets affected by this disorder at some point during their lives and girls are more likely to experience this disorder than boys.Market DriversIncreasing prevalence of chronic depressive personality disorder is driving the market growthIncrease in diagnosis of chronic depressive personality disorder also acts as a market driverLong term treatment requirement is accelerating the growth if this marketIncrease in initiatives by government and non-government organizations regarding mental disorders by awareness campaigns and conferences is also boosting the market growthMarket RestraintsEffectiveness of psychotherapy alone is hindering the market growthLack of approved drug for chronic depressive personality disorder is restraining the market growthNon-medicated treatments are available for this disorder which acts as a market restraintSegmentation: Global Chronic Depressive Personality Disorder Treatment MarketBy Mechanism of ActionSelective Serotonin Reuptake Inhibitors (SSRIs)Tricyclic Antidepressants (TCAs)Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)By DrugsAmitriptylineBupropionSertralineDuloxetineBy DiagnosisPhysical ExamLab TestsPsychological EvaluationBy TreatmentMedicationPsychotherapyBy Distribution ChannelHospital PharmacyRetail PharmacyOnline PharmacyBy End-UsersHospitalsHomecareSpecialty ClinicsBy GeographyNorth AmericaU.S.CanadaMexicoEuropeGermanyItalyU.K.FranceSpainNetherlandsBelgiumSwitzerlandTurkeyRussiaRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaAustraliaSingaporeMalaysiaThailandIndonesiaPhilippinesRest of Asia PacificSouth AmericaBrazilRest of South AmericaMiddle East & AfricaSouth AfricaRest of Middle East & AfricaKey Developments in the MarketIn March 2019, Johnson & Johnson Services, Inc received the U.S FDA approval for Spravato (esketamine), nasal spray for use in patients with treatment-resistant depression (TRD) a type of major depressive disorder (MDD).
Market Analysis and Insights:- Global Chronic Depressive Personality Disorder Treatment MarketGlobal Chronic Depressive Personality Disorder Treatment Market By Mechanism of Action (Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)), Drugs (Amitriptyline, Bupropion, Sertraline, Duloxetine), Diagnosis (Physical Exam, Lab Tests and Psychological Evaluation), Treatment (Medication and Psychotherapy), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2026 Market Analysis: Global Chronic Depressive Personality Disorder Treatment MarketGlobal chronic depressive personality disorder treatment market is growing at a steady CAGR in the forecast period of 2019-2026.
The report contains data of the base year 2018 and historic year 2017.
This rise in market value can be attributed to the increasing prevalence of depressive personality disorder, increase in diagnosis, requirement for long term treatment and increase in initiatives by government and non-government organizations regarding mental disorders by awareness campaigns and conference are some factors fueling the market growth.Market Definition: Global Chronic Depressive Personality Disorder Treatment MarketChronic depressive personality disorder is also known as dysthymia is a form of depression which is mild but continuously remains for several years.
A patient with chronic depressive personality disorder have symptoms such as lost interest in normal activities, hopelessness, low self-esteem, low appetite, low energy and an overall feeling of inadequacy.
These feelings interfere with the patient’s personal and social relationship, profession and daily activities.
This disorder can affect children and adolescents, approximately 11.2% of 13 to 18 years olds gets affected by this disorder at some point during their lives and girls are more likely to experience this disorder than boys.Market DriversIncreasing prevalence of chronic depressive personality disorder is driving the market growthIncrease in diagnosis of chronic depressive personality disorder also acts as a market driverLong term treatment requirement is accelerating the growth if this marketIncrease in initiatives by government and non-government organizations regarding mental disorders by awareness campaigns and conferences is also boosting the market growthMarket RestraintsEffectiveness of psychotherapy alone is hindering the market growthLack of approved drug for chronic depressive personality disorder is restraining the market growthNon-medicated treatments are available for this disorder which acts as a market restraintSegmentation: Global Chronic Depressive Personality Disorder Treatment MarketBy Mechanism of ActionSelective Serotonin Reuptake Inhibitors (SSRIs)Tricyclic Antidepressants (TCAs)Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)By DrugsAmitriptylineBupropionSertralineDuloxetineBy DiagnosisPhysical ExamLab TestsPsychological EvaluationBy TreatmentMedicationPsychotherapyBy Distribution ChannelHospital PharmacyRetail PharmacyOnline PharmacyBy End-UsersHospitalsHomecareSpecialty ClinicsBy GeographyNorth AmericaU.S.CanadaMexicoEuropeGermanyItalyU.K.FranceSpainNetherlandsBelgiumSwitzerlandTurkeyRussiaRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaAustraliaSingaporeMalaysiaThailandIndonesiaPhilippinesRest of Asia PacificSouth AmericaBrazilRest of South AmericaMiddle East & AfricaSouth AfricaRest of Middle East & AfricaKey Developments in the MarketIn March 2019, Johnson & Johnson Services, Inc received the U.S FDA approval for Spravato (esketamine), nasal spray for use in patients with treatment-resistant depression (TRD) a type of major depressive disorder (MDD).
11 February 2020 - Global Human Growth Hormone (HGH) Market is anticipated to witness an exponential growth in the forecast period.
Human growth hormone is mainly responsible for regeneration and growth among humans and stimulates cell reproduction.
Factors such as presence of a large pool of patients, technological advancements, demand for better-quality and cost-effective human growth hormones, increasing compliance for human growth hormone drugs and massive unexplored markets in the developing economies, such as China and India.Furthermore, advanced research and development services, and new drug developments by the key companies, increasing occurrences of human growth hormone deficiency diseases, and growing aged population are likely to propel the human growth hormone industry in the forthcoming period.
Human growth hormone (HGH) industry is anticipated to expand at a CAGR of 7.5% in the upcoming period as the scope, product types, and its applications are increasing across the globe.Human growth hormone market could be explored by route administration, application, distribution channel, and geography.
It is likely to witness substantial growth in the years to come.
The key factors that could be attributed to the growth of the market include the preference for the subcutaneous technique is rising as it leads to the important growth in development rates and low occurrence of antibody progress.
Global Human Growth Hormone (HGH) Market is anticipated to witness an exponential growth in the forecast period.
Human growth hormone is mainly responsible for regeneration and growth among humans and stimulates cell reproduction.
Factors such as presence of a large pool of patients, technological advancements, demand for better-quality and cost-effective human growth hormones, increasing compliance for human growth hormone drugs and massive unexplored markets in the developing economies, such as China and India.Furthermore, advanced research and development services, and new drug developments by the key companies, increasing occurrences of human growth hormone deficiency diseases, and growing aged population are likely to propel the human growth hormone industry in the forthcoming period.
On the other hand, the high cost of treatment, strict governing approvals, and adverse effects associated with the usage of synthetic human growth hormones are anticipated to hinder human growth hormone drugs market growth in future.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/human-growth-hormone-drugs-market/request-sampleHowever, increasing acceptance of growth hormone drugs, as anti-aging drug and the rising popularity of human growth hormone drugs is likely to create lucrative opportunities for the market.
Human growth hormone (HGH) industry is anticipated to expand at a CAGR of 7.5% in the upcoming period as the scope, product types, and its applications are increasing across the globe.Human growth hormone market could be explored by route administration, application, distribution channel, and geography.
It is likely to witness substantial growth in the years to come.
